Dr. Lara Nyman, Ph.D. is the Vice President of Research & Discovery at AG1 ( https://drinkag1.com/learn/research/scientific-research ), responsible for leading the company's innovative research efforts to develop cutting-edge nutritional products. In this role, she oversees the research and development of new formulations, ensures the scientific integrity of product claims, and collaborates with cross-functional teams to drive product innovation.
Dr. Nyman previously served as the Chief Scientific Officer at Weo, a water augmentation company, providing strategic guidance and scientific oversight to the company's product development and research initiatives, working closely with their R&D team to identify emerging trends, evaluate new technologies, and translate scientific insights into compelling consumer offerings.
Prior to Weo, Dr. Nyman served as Senior Principal Scientist in the Claims Center of Excellence for Consumer Health & Wellness at PepsiCo, leveraging her deep understanding of consumer needs and scientific principles to develop innovative, evidence-based claims for the company's health and wellness products.
Dr. Nyman holds a Master of Science (MS) in Exercise Physiology from Southern Connecticut State University, a Ph.D. in Cellular and Molecular Physiology from University of Alabama at Birmingham, and was a Post-Doctoral Fellow, Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism at Vanderbilt University School of Medicine.
Welcome, everybody, again to another episode of our show, bringing another really awesome
guest today involved in science and technology, creating a better tomorrow for all of us.
Today on the show, we have the honor of being joined by Dr. Laryn Nyman, who is the Vice
President of Research and Discovery, AG1. There, she is responsible for leading the company's
innovative research efforts to develop cutting-edge nutritional products.
She oversees the company's R&D of new formulations. She ensures the scientific integrity of the
various product claims and ultimately collaborates with their cross-functional
teams to drive product innovation. Prior to this role, she served as the Chief Scientific
Officer of a company called Weyo, which is a water augmentation company, providing all sorts
of strategic guidance and scientific oversight to their R&D team. And prior to that, was a Senior
Principal Scientist in the Claims Center of Excellence for Consumer Health and Wellness
at PepsiCo. They are leveraging a broad understanding of consumer needs, scientific
principles, ultimately to develop innovative evidence-based claims for their company's health
and wellness products. Dr. Nyman holds a Master's in Exercise Physiology from Southern
Connecticut State University, went on to do a PhD in Cellular and Molecular Physiology from
University of Alabama at Birmingham, and then did a postdoc fellow in the Department of Medicine,
Division of Diabetes, Endocrinology, and Metabolism at Vanderbilt University School of Medicine.
A lot to get into today. We're really looking forward to these topics.
Dr. Laryn Nyman, thank you so much for taking the time to come on the show.
Ira, thank you so much for the invite and the very thorough introduction. It's a pleasure to
be here with you and your listeners today. Really great having you. Yeah, I'm looking
forward to all these themes. Would love to start off at the beginning, though. I mean,
taking a look at some of your early research, both your Master's and your PhD, focused on a really
interesting compound known as carnitine palmitoyl transferase 1A, CPT1A, which has all sorts of
interesting things to do with regard to fatty acid metabolism for normal development and exercise and
everything else. Would love to hear the backgrounds of how, you know, this topic, this interest fell
into your lap originally. Yeah, that's great. Thank you again. I'll start, you know, with my
PhD and my postdoc work because they were really foundational in shaping how I think about
metabolism, physiology and research as a whole. Firstly, I think I'm unique in that I absolutely
loved my PhD at University of Alabama, Birmingham. It was a fantastic experience. I also loved my
postdoctoral fellowship at Vanderbilt, also a fantastic experience. I actually didn't want
either of them to end. I think I'm alone in saying that, but I really did have a fantastic
experience. I loved the research process. I loved, you know, asking questions and, you know,
waiting for the answers. I loved doing experiments and, you know, seeing if they were fruitful or not.
I just really was excited by the whole research process. Initially, I went to graduate school
thinking that I would continue clinical level investigation of things. I was really interested
in hormonal regulation of metabolism. I'm still really interested in that. I think that's really
my underlying passion. I don't know if that's going to ever go away.
But I had, you know, the intentions of studying clinical level study. And then once I started to
take courses, especially in molecular biology and fatty acid oxidation, I got really hooked
on, you know, the molecular level study of things. And I was really fascinated with, you know,
how people get to be in obese states and also develop metabolic syndrome and diabetes.
And I, at the time, was convinced that, you know, this molecular level study was going to
get me further in terms of understanding the mechanisms of action and how those diseases
develop. And so I ended up joining a molecular genetics lab that focused on fatty acid
oxidation disorders. I will say that the majority of the people in that lab were interested in fatty
acid oxidation disorders more for the inborn errors of metabolism angle. So I don't know if
you're familiar with SIDS, but there are some that believe that inborn errors of metabolism
are at least partly responsible for some of the sudden infant deaths that happen in children.
And so I came at it from a slightly different angle because I was interested in inborn errors
of metabolism as a potential explanation for mechanism of action for the development of
diabetes and obesity. However, once, you know, we were intending to essentially shut down the
system and use gene knockout models, challenge them with diets, and then see what happens and
see if they develop that phenotype. And then towards the end of that postdoc, I got really
interested in insulin secretion, again, on my quest to find out the mechanism for the development
of this disease and related diseases. And so I went on to Vanderbilt, which has a fantastic
diabetes and metabolism department. I got to work with Dr. Alvin Powers and Dr. Dave Histon,
who at the time was more focused on imaging. And so I got a two for one, if you will. So
both mentors were fantastic, but they had different expertise. And there, my focus of
work was on pancreatic islet biology and vascular dynamics. And it was really interesting. I got to
use really cutting edge at the time, advanced imaging technology. And I was able to develop
methods around imaging pancreatic islet blood flow in vivo. And for those of you who don't
know what pancreatic islets are, they're these really cool clusters of insulin, glucagon, and
other hormone producing cells. And so we were interested not only in their arrangement,
but in the order and the vasculature around these cells. So the delivery of blood flow
to these cells, we thought potentially also could impact diabetes development essentially.
And so again, that was the first time that people were able to see the vasculature and live blood
flow in the living animal. And so it was a breakthrough in a sense. And I loved it. It
was super fascinating. But towards the end of that event, which is 10 years now, I've just
essentially summed up 10 years, I was interested in getting closer to having more of a translational
impact. And so I wanted to get back to more applied research.
And this is where you transition to PepsiCo. And it's interesting. And again, just for the
audience, the work that you published at Vanderbilt in terms of the structural dynamics of blood flow
and all that in the pancreas is equally impressive to the sort of the molecular biology work. And
we'll be getting back to that in a little bit when we talk about sort of the future of personalized
nutrition and all that. But the interesting thing at your time at PepsiCo, and I've had a bunch of
your former colleagues on the show, including James Carter from Gatorade and all that. And
you published with him on nitrate supplementation and all that. You did some very interesting work
on sleep and physical performance, which is an extremely hot topic nowadays.
But the very interesting thing in this work, you were pointing out that, look,
you know, this sleep-wake cycle isn't one thing. You know, you were pointing out it's serotonin,
it's GABA, it's melatonin, it's all this other important neurochemistry. One thing isn't going
to help with that. We need to think of synergies, and this is going to get to this theme as we get
to athletic greens and so forth, in the principle of nutrient synergy and what you're capable of
doing, let's say, much more than we are in the pharma industry in the consumer packaged goods
space. Talk a little bit about your time, you know, working on these interesting combination
formulas for sleep. But at the same time, what did you learn in terms about, you know, how you
need to think about synergy as you're creating these products? So, again, I'll take a little
bit of a step back and I'll start broader, and then maybe we can get, you know, closer into
synergy specifically. But I would say, firstly, you know, my time at Pepsi and Gatorade were
fantastic training ground for me. I spent 11 and a half years there working with fabulous people,
driving and supporting more than 35 products in 25 countries, so amazing experience period, right?
And I am really grateful for all the opportunities I had to collaborate both
internally and externally, and we had some fantastic external collaborators in the sleep
space as well. But, you know, if I had to summarize, you know, that entire tenure, I'd say there are
three main lessons, learnings, if you will. The first is that science-led innovation has a massive
amount of opportunity, and, you know, the opportunities are virtually endless. If you're
just a little bit creative and willing to look just a little bit below the surface,
and that's where academic collaborations can come in, there's just a huge amount of opportunity
out there. The second is that strategy is really important, so you can have like a robust scientific
breakthrough, but that's just the beginning. And, you know, thinking or starting with the end in
mind is really key. You can't just be thinking about, you know, your next move, you've got to be
thinking about the whole board. And the third is that cross-functional engagement early is essential,
right? So if you want to develop a product, whether it's sleep, whether it's sports,
you have to understand, you know, what market you plan to launch in, what are their, you know,
regulatory product specifications, what is acceptable evidence for them in that market.
So, you know, partnering with regulatory, partnering with consumer insights to understand
the cultures, all those things are really essential early on. And so while, you know,
we did a number of external collaborations with academics, there's a huge amount that goes into
product innovation on top of research. So tell us, you know, so 11 years at PepsiCo,
you know, you arrive at Athletic Greens. Just talk a little bit about how you got there,
why you decided to make the move, and just explain your current role, Vice President
of Research and Discovery, because it's a quite comprehensive, you know, a portfolio that you
oversee now in terms of not just R&D, but compliance, and a lot of other aspects that
introduce the company in general, too, if you would take a little time.
Sure. So our vision as a company is to be the most trusted foundational nutrition and gut health
product brand. We're developing, you know, innovative products and services to give people
ownership of their health. And so as part of that, my role as VP of Research and Discovery
is to position AG1 as a science-first brand. And that's through a long-term research strategy that's
centered around clinical validation, scientific rigor, partnerships with academics, a strong
presence at scientific conferences, robust and credible publication pipeline, hosting of academic
summits, scholarships, you name it. We want everyone to know that we are a science brand.
And then the second piece of my role is developing and evolving a science-led innovation strategy
that is rooted in AG1's unique value proposition, so that we're not just competing and producing
MeToo products, but we're leading the category. And then the third mission is to develop my team
of brilliant and passionate scientists to do their best work. And let's start off sort of at the
beginning of that, because, you know, and again, one of the themes that we've gotten into a bit
on the show lately is sort of this principle, I mean, in the United States of these food deserts,
where there's a tremendous millions of people in their country, for instance, that don't live near
to a decent source of fresh fruits and vegetables, you know, you're, you know, you focused a lot on
this principle of nutrient gaps. And when you were talking about sort of foundational nutrition, I
mean, I think we think a lot about sort of the futuristic high-tech stuff, the nutrigenomics and
all that, which we'll get to, but still we overlook this basic fact that in the United States, there's
a lot of people that just do not have access to the nutrients that typically would come with a
decent diet, hence AG1. And, you know, you've published on this in terms of not just the
principle of nutrient status, nutrient gaps, but, you know, how we actually use biomarkers and
clinical trials. Talk about what that means, talk about what nutrient status, what nutrient gaps are
all about, because I think this is a sort of core to this, sort of the base of what AG1 is all about.
Yeah, I think this is a really fascinating topic and one that was new to me when starting
AG1. I mean, I didn't dive deep into it until on my role here, but it's really fascinating.
To your point, or to what you just said, I don't think a lot of people realize that, you know,
even healthy eaters have nutrient gaps. In fact, my team is collaborating with Texas Tech
on a publication that should be coming out in the British Journal of Nutrition soon,
where we've identified sex differences in nutrient gaps in active adults. And it's
just really eye-opening, and that's on top of the four clinicals that we've just completed,
demonstrating, again, that, you know, even, you know, the third, you know, non-third world,
Western society population has nutrient gaps, and they're quite common. And so, yes, we have
ongoing kind of problem state work that we're working on in collaboration with academics
to dive deeper into that. And I do think that that is something that is unique to AG1 and that
I'm very excited about. And, you know, coming back to the thing we talked about when we were
chatting about Pepsi, but clearly, and you can go into sort of, because I know, you know,
AG1 represents, as you say, the company sort of these whole body benefits in a scoop and, you
know, combining all these different concepts in terms of gut health and energy production, so
forth. Talk a little bit about, again, the principle of nutrient synergy here, because,
and I know some of your team has written on this in terms of how, you know, what is involved,
the challenges in investigating when, you know, not just putting one or two or three nutrients
together, but when you start putting 50 and 60 and 70, but nonetheless, extremely important
in this day and age where we have technologies to, you know, whether it's what you were speaking
about earlier or other technologies that are coming along. How does AG1 look at nutrient
synergy? And ultimately, how does that sort of play a role in how you craft some of these clinical
trials that you get involved in? Absolutely. So, firstly, maybe we should ground the
listeners in, you know, what AG1 is. And so, AG1 is a daily health drink that includes prebiotics,
probiotics, multivitamins, and nutrient-dense superfoods all into one scoop. And so, to your
point, the idea is that these or this combination of ingredients works better together. And that
is based on the fundamental idea that, you know, optimizing the microbiome
for nutrient absorption and bioavailability enhances, you know, not just the intake
of vitamins, but the processing and absorption of them. And, you know, that is being studied
as we speak. I mean, the microbiome is a very hot area, and there is a recent uptick in interest
specifically on how to optimize the microbiome for nutrient absorption. And one of the examples
on what you're doing there is something called symbiotic development. Now, so I guess people
listening to the show may be familiar with pre and probiotics. It's sort of almost you're creating
another class here of sort of the interaction between the two. Explain what a symbiotic is,
and a little bit, because I know you've published recently, actually, this is just last month,
both on, you know, comparing symbiotics to traditional probiotics and some of what you've
seen there. But go a little into that if you wouldn't, but the world of symbiotics.
It's the idea that we're essentially feeding the microbes or we are enhancing
the activity of the probiotics by supplementing with prebiotics, so essentially food for them,
right? And we are increasing the chances or the production of the secondary metabolites,
i.e. short chain fatty acids, which are known to have beneficial downstream effects.
And in terms of some of the, you know, because again, we're going back to your Vanderbilt work
and thinking about imaging technology and some of, you know, how that's evolved over this.
Obviously, we have a new toolkit with us in 2025. What, can you talk a little bit,
because again, when you start studying these materials, some of which are combinations,
some of which are living, things get a little more complicated. Obviously, we have AI, we have,
you know, all the genomic tools that have evolved. What are the tools that get you excited? What are
you interested in using at AG1 as far as it comes to, you know, analyzing whether it's the in vitro
work, in vivo work, clinical studies? Take us into some of your vision for sort of the supporting
technologies around this, well, I'll call this sort of the nutrigenomic space. Yeah. So again,
I am really proud of what we're doing here at AG1. Not only do we have preclinical and clinical work
that we are invested in, but we are using advanced omic technologies. And as with the
microbiome space as a whole, we're getting beyond just what's there, but what are they doing?
And so we have recently started to invest in metagenomic studies, looking more at functionality
versus just what's there. We're using whole genome sequencing versus just 16S. So we are really
excited about those technologies. And yes, AI, I'm sure that question is coming. You know, everyone
is excited. It's no secret that AI has huge potential, and we are exploring the use of AI
to see if we can use it to drive efficiencies and our innovation portfolio even further.
And continuing along those lines, and this is interesting. I spent a small part of my career,
which was mainly in pharma, but I sort of stepped into consumer goods at one point.
There was a hybrid area known as sort of the botanical drug back in the day that the FDA
created, and it was thinking about ultimately how we could access some of the potential of
phytochemicals and phytochemical mixtures, not just as consumer products, but also on the
therapeutic side. It didn't really take off that well because pharma was really good at developing
those complex combinations. But it is interesting when we learn about what some of these natural
phytochemicals and mixtures can potentially do. Are there indications? I mean, we've talked about
some of them. Obviously, you're very into the metabolic side, and I've seen, again, looking at
some of the papers that AG1 is putting out there in terms of inflammation, in terms of healthy gut
and all that. Any interesting indications that you can mention, whether AG1 is working or not,
but in general that excite you in terms of the potential of not just phytochemicals and the
unique chemistry that they provide, but what the combinations can do versus, say, single-molecule
drugs? Again, I'm going to speak for myself. I am super excited about the potential for cognition
and mitigating some of the speedier or more vulnerable processes in cognitive decline
that happen in normal aging. I think that is a huge opportunity area. Obviously, there's a
metabolic space. There's a huge number of other opportunities, but that's one that I'm particularly
excited about. You just mentioned aging, and I have to ask, because I did notice one of your
papers, and I think this was from about a year ago in the journal Aging, and it had to do with
senescence. This is a previous company, but nonetheless, this whole area of senescence,
of what we'll call healthspan, it's sort of early now, but it's taking off a lot in the topic of,
you know, how we can, as opposed to sort of looking at the targets of these diseases,
ultimately interfere earlier on with some of these aging mechanisms, senescence being one of them.
Are you excited about the aging space? And I don't mean just sort of the disease of aging,
but sort of the larger aging picture, because I think that's a very sweet spot, again, for
the potential of these interesting combination products. I agree completely. Firstly, you know,
the demographics alone are staggering. Something like 20% of the population is going to be 65 or
older by the year 2050. So if you're not thinking about it, I would say you're behind the curve
already. So it's something that we have to pay attention to, and I think there's a lot of
opportunity. You know, while aging is a universal experience, I would say that healthspan,
you know, varies. So we have an opportunity to positively impact healthspan by
intervening earlier. So we don't want to wait until someone's 70 and already experiencing cognitive
decline to, you know, try nutritional intervention. We want to start decades earlier, and we know that
there are very strong associations between nutrient deficiencies and frailty and cognitive
decline. So I do think we have a right to win in that space in particular. Absolutely. And yeah,
I mean, that's the whole area of, and again, this comes back to, you know, sort of the formulation
side and all that, you know, the whole issue of compliance, which I'm guilty of myself, you know,
I have to take whatever, my magnesium, because I got, you know, slightly elevated blood pressure,
I got to take a lot of it, it's hard to take, and sort of, you know, this other angle, which I,
you know, we sort of glossed over. I think it's kind of important that the formulations and the
ability, you know, in case of, you know, taking a drink or whatever to satisfy, as opposed to the
20 some odd pills I got to take, like, just a very important piece of it. We can't overlook
the importance of non-compliance, because that's a big number that impacts the system. So
it's, I just want to throw that out there as well. When, last, it was two months ago, you hosted the
first, it was the AG1 Nutrition and Gut Health Summit, bringing together, you know, scientists
from across the field. What else is going on in terms of this part of the organization, if you
talk about that? Because clearly, you know, a lot of cutting-edge science out there, you know,
as you've done throughout your career, got to keep up to speed on what's next and bringing the
best minds together, the thought leaders. Talk about the summit and also what else is coming
up in terms of related things that AG1's doing. Yes, absolutely. So firstly, the Nutrition and
Gut Health Summit that you just mentioned was a milestone event for us. I'm thrilled over it.
It was fantastic. We brought experts from diverse backgrounds in nutrition and gut health,
and they spoke on different areas of expertise. They shared some cutting-edge stuff with us. It
was fantastic. We got really good feedback, and we're already planning next year's event.
So I'm excited to continue and keep that momentum going forward. I do think that relationships
with academics is essential, not only for supporting and driving the science forward,
but also for staying close to cutting-edge science to drive innovation. So again, we have a number of
events that are upcoming, and not all of them are going to be public-facing, but they are definitely
on our radar. And again, we're just getting started. There's going to be many more.
And then just to follow up to that question, what should we be on the lookout for in terms of
Dr. Lahren-Eymann for the rest of the year as we get further into 2025,
other conferences, talks, places that we can run into you and meet you,
anything else that I did not touch on while we have you today, please?
Let me talk a little bit about our research and our team. So firstly, I mentioned previously,
I'm really proud of the fact that number one, that we're invested in preclinical and clinical
discovery, and we're invested in research overall. I have a brilliant team of passionate scientists
in diverse areas, so they have a wide range of expertise from clinical nutrition to academic
nutrition to microbiology to metabolism and more. My team is presenting at conferences as we speak.
We have had, I think, eight abstracts accepted this year. And so we have a number of publications
that are in the works. So please do be on the lookout for those. We just submitted three more
abstracts, so we will be presenting pending their acceptance at FENCI coming up in Nashville this
year. In addition to that, we, again, have a number of thought leadership projects that we are
either driving or collaborating with academics on. We are really interested in establishing
new methodology for probiotic enumeration, which is important not only for the probiotic or
functional food space, but also for the food safety and pathogenic bacteria enumeration.
And again, we have projects going on to identify nutrient gaps in different populations
and more. So we are not just watching the science, we're actually participating in it.
And we have a fantastic team. And so, I mean, I'm super excited for all this ahead.
Yeah, we will, you know, on your website, there is a, you know, a research tab. And again,
it's quite fascinating. We'll put the link to this in the show notes, you know, all the peer
reviewed research and clinical studies and everything else that you're focusing on here,
plus the future looking stuff in terms of the genomics and all that. So it's pretty impressive.
Yeah, again, I very much enjoy, you know, walking through your history here and seeing where it all
started, thinking about the fatty acid metabolism and now on to the future of all things,
nutrigenomics and closing nutrient gaps and all that, but really an impressive story. So I'm
thankful that you shared it with us. And I look forward to, you know, continue to follow the
company and you and your team. And again, we will put the link to all of that in the show notes.
But again, for everybody that is going to be listening to this episode of the show
across the various podcast networks or who will be watching on our YouTube channel, again,
you've been spending time with Dr. Lara Nyman, Vice President of Research and Discovery at AG1.
Lara, I want to thank you for taking the time out of your schedule to come talk to us for a
little while about what you're up to, what you've been doing. Thank you for everything you've been
doing for closing this nutrient gap. And then, you know, as we like to say on our show, thanks for
helping to create a better tomorrow for many people out there via the type of science and
technology you're championing. Really impressive. All right. Thank you so much for the opportunity.
It's been my pleasure. Really great having you.